Since tumor escape due to immunoediting is a key challenge to implementing CAR T cells in solid tumors, Tian and colleagues examined the ability of BiCisCAR T cells to overcome heterogenous antigen expression by using neuroblastoma cell lines that had CRISPR mediated ablation of GPC2 or CD276. Here, GPC2 is linked to neuroblastoma.